It's beyond Hype.......they have now officially taken what was a brilliant branding strategy (personifying the intangible and making it both relatable and revolutionary sounding) and turned it into pure silliness. The Phytel acquisition last year was when my red-flags were raised being that Pop HeAlth is still just a buzzword, vapor and yet to be proven, but this addition just confirms that IBM is just trying to over-PR their revenue shell game. What is funny is that Truven began as the mixed bag busines unit Thomson Reuters after they went on a silly publishing buying binge while the publishing world was crashing (PDR, Micromedex, etc). . Thomson couldn't find a way to blend those brands well into their financial and media strategies, and spun them off which resulted in Truven. How IBM is going to find a better fit for these out-of-date brands who were too out-of-date for an old publishing co company is beyond my logical understanding. It makes me speculate that IBM may want to closely observe what is currently happening to Xerox.......
Bottom line, I no longer view Watson with the shock-and- awe wonderment that I once did.
hackerDoc - 8 years ago
Of the very small minority of medical informaticists who are computer scientists and physicians -- those who have the expertise and experience to design and build clinical AI systems -- which ones work for IBM or Truven Analytics?
The recent announcement that IBM's pending acquisition of Truven Analytics will give IBM 300 million patient lives -- 90% of the US population -- for Watson to work with scares me.
I'm not comfortable with IBM having access to my medical information. Are you?
Eva Destruction - 8 years ago
Healthcare seems more comfortable in the dark ages than embracing and supporting cognitive technologies.
Cynical - 8 years ago
A REALLY expensive hype.
MEHIS Expert - 8 years ago
All what we see of IBM Watson is them driving consultancy fees. Great visionary presentations but the technology is outdated. They will keep buying companies for their revenue stream, installed base and consultancy potential and not technological innovation.
It's beyond Hype.......they have now officially taken what was a brilliant branding strategy (personifying the intangible and making it both relatable and revolutionary sounding) and turned it into pure silliness. The Phytel acquisition last year was when my red-flags were raised being that Pop HeAlth is still just a buzzword, vapor and yet to be proven, but this addition just confirms that IBM is just trying to over-PR their revenue shell game. What is funny is that Truven began as the mixed bag busines unit Thomson Reuters after they went on a silly publishing buying binge while the publishing world was crashing (PDR, Micromedex, etc). . Thomson couldn't find a way to blend those brands well into their financial and media strategies, and spun them off which resulted in Truven. How IBM is going to find a better fit for these out-of-date brands who were too out-of-date for an old publishing co company is beyond my logical understanding. It makes me speculate that IBM may want to closely observe what is currently happening to Xerox.......
Bottom line, I no longer view Watson with the shock-and- awe wonderment that I once did.
Of the very small minority of medical informaticists who are computer scientists and physicians -- those who have the expertise and experience to design and build clinical AI systems -- which ones work for IBM or Truven Analytics?
The recent announcement that IBM's pending acquisition of Truven Analytics will give IBM 300 million patient lives -- 90% of the US population -- for Watson to work with scares me.
I'm not comfortable with IBM having access to my medical information. Are you?
Healthcare seems more comfortable in the dark ages than embracing and supporting cognitive technologies.
A REALLY expensive hype.
All what we see of IBM Watson is them driving consultancy fees. Great visionary presentations but the technology is outdated. They will keep buying companies for their revenue stream, installed base and consultancy potential and not technological innovation.